Assembly Biosciences, Inc. reported significant financial developments in its 2025 10-K filing, with collaboration revenue reaching $72.3 million, a 154% increase from $28.5 million in 2024. This surge was primarily attributed to a $35 million payment from Gilead Sciences, Inc. following the exercise of its option to license Assembly's helicase-primase inhibitor (HPI) program for recurrent genital herpes. The company also recognized an additional $10 million from a prior amendment to the collaboration agreement. Despite this revenue growth, Assembly remains unprofitable, with an accumulated deficit of $832 million as of December 31, 2025, and expects to continue incurring substantial operating losses as it advances its clinical pipeline.
In terms of operational metrics, Assembly's research and development expenses increased by 16% to $64.8 million, driven by higher external program costs associated with ongoing clinical studies for its HPI candidates, ABI-5366 and ABI-1179. The company reported positive interim results from Phase 1b studies for both candidates, demonstrating significant reductions in HSV-2 shedding rates compared to placebo. Additionally, the company is preparing for Phase 2 studies for its HPI program, with Gilead expected to initiate these trials in 2026.
Assembly's workforce consisted of 73 employees as of December 31, 2025, with the majority based in South San Francisco, California. The company has focused on building a strong leadership team with extensive experience in virology and drug development. The collaboration with Gilead is seen as a critical component of Assembly's strategy, providing both financial support and expertise in late-stage development and commercialization.
Looking ahead, Assembly's outlook remains cautious, as it continues to rely on external funding to support its research and development activities. The company has indicated that it may need to raise additional capital to fund its operations and product development, particularly if it opts to participate in the profit-sharing arrangement with Gilead. The ongoing geopolitical and economic uncertainties could also impact its ability to access capital markets. Overall, while the collaboration with Gilead presents significant opportunities, the company faces challenges in achieving profitability and advancing its product candidates through the regulatory process.
About ASSEMBLY BIOSCIENCES, INC.
Assembly Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics for serious viral diseases. Its pipeline includes clinical-stage therapies targeting recurrent genital herpes, hepatitis delta virus (HDV), and hepatitis B virus (HBV). With significant market opportunities, Assembly aims to address unmet medical needs through collaborations, notably with Gilead Sciences. The company is advancing multiple candidates towards clinical readouts, enhancing treatment options for patients worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.